Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced details about its Phase 2 FILLY study...
Multi-center platform trial sponsored by the Healey Center will simultaneously assess multiple drug regimens Zilucoplan selected by leading experts in ALS as one of the first therapeutic candidates to be tested BOSTON & CAMBRIDGE, Mass.–(BUSINESS...
DURECT Corporation (Nasdaq: DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic hepatitis (AH). The final enrollment for the trial consists of 12 severe patients (MELD 21-30) and 7...
TrialSpark, a technology company committed to improving the speed, access, and reliability of clinical trials, and Pfizer have entered into a multi-year collaboration to extend Pfizer clinical trials to community doctors who have not previously been study...
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor...
Study will yield reliable benchmarks on trial cost and efficiency, enabling participants to realize dramatic cost savings The WIRB-Copernicus Group®’s (WCG™) Clinical Services Division is pleased to announce that enrollment in WCG KMR Group’s 2019 Clinical...
Email
Text